Scoring Systems of Peritoneal Dissemination for the Prediction of Operative Completeness in Advanced Ovarian Cancer

Background/Aim: We investigated the predictive value of scoring systems of peritoneal disseminations for complete surgery (CS) at primary debulking surgery (PDS) in advanced ovarian cancer. Patients and Methods: We retrospectively enrolled eligible patients with clinical stages III or IVA selected for PDS from January 2015 to December 2019. Concern variables were predictive index value (PIV) and peritoneal cancer index (PCI) from operative and pathological reports. Primary endpoints were cutoffs to predict operative completeness using the receiver operating characteristic curve. Results: Among 111 patients, PIV ≥8 and PCI ≥13 were the best predictors of incomplete PDS, including optimal and suboptimal surgeries (AUC=0.821 and 0.855, respectively). CS rates in PIV ≤6 and PCI ≤12 were significantly higher than in PIV ≥8 (89.3% vs. 47.2%; p<0.05) and PCI ≥13 (90.9% vs. 41.2%: p<0.05). Conclusion: PIV and PCI are potential predictors for CS at PDS.

[1]  E. Boldo,et al.  Validation of three predictive models for suboptimal cytoreductive surgery in advanced ovarian cancer , 2021, Scientific Reports.

[2]  D. Matei,et al.  Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  S. Klaschik,et al.  Risk Factors for Severe Complications in Ovarian Cancer Surgery , 2020, In Vivo.

[4]  G. Scambia,et al.  Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850) , 2020, International Journal of Gynecological Cancer.

[5]  A. Gryparis,et al.  Predicting complete cytoreduction for advanced ovarian cancer patients using nearest-neighbor models , 2020, Journal of Ovarian Research.

[6]  A. Okamoto,et al.  Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept , 2020, Journal of gynecologic oncology.

[7]  N. Yanaihara,et al.  Neoadjuvant Chemotherapy for Patients With Diaphragmatic Lesions: A Prognostic Postoperative Analysis , 2020, In Vivo.

[8]  A. Okamoto,et al.  Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. , 2020, European journal of cancer.

[9]  J. Sehouli,et al.  Pre-operative serum CA125, peritoneal cancer index and intra-operative mapping score as predictors of surgical results in primary epithelial ovarian cancer , 2019, International Journal of Gynecological Cancer.

[10]  T. Enomoto,et al.  Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO-JSOG joint study. , 2019, Gynecologic oncology.

[11]  M. Leeflang,et al.  Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer. , 2019, The Cochrane database of systematic reviews.

[12]  Zheng Feng,et al.  A triage strategy in advanced ovarian cancer management based on multiple predictive models for R0 resection: a prospective cohort study , 2018, Journal of gynecologic oncology.

[13]  A. Soliman,et al.  Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study , 2018, Geburtshilfe und Frauenheilkunde.

[14]  N. Zeff Role of laparoscopy in initial tumour staging in advanced epithelial ovarian cancer: A systematic review , 2018, Pleura and peritoneum.

[15]  C. Ngô,et al.  A pre-operative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer , 2017, PloS one.

[16]  A. Reuss,et al.  TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33 / AGO‐OVAR OP7). , 2017 .

[17]  P. Valette,et al.  A new internet tool to report peritoneal malignancy extent. PeRitOneal MalIgnancy Stage Evaluation (PROMISE) application. , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  G. Scambia,et al.  Current Recommendations for Minimally Invasive Surgical Staging in Ovarian Cancer , 2016, Current Treatment Options in Oncology.

[19]  H. Kitchener,et al.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial , 2015, The Lancet.

[20]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[21]  P. Morice,et al.  Accuracy and Reproducibility of the Peritoneal Cancer Index in Advanced Ovarian Cancer During Laparoscopy and Laparotomy , 2013, International Journal of Gynecologic Cancer.

[22]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[23]  R. Rouzier,et al.  Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer. , 2010, American journal of obstetrics and gynecology.

[24]  R. Rouzier,et al.  External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score. , 2008, Gynecologic oncology.

[25]  E. Cotte,et al.  Quantitative prognostic indices in peritoneal carcinomatosis. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[26]  G. Scambia,et al.  A Laparoscopy-Based Score To Predict Surgical Outcome in Patients With Advanced Ovarian Carcinoma: A Pilot Study , 2006, Annals of Surgical Oncology.

[27]  G. Georgiadis,et al.  Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[28]  K. Jablonski,et al.  Prognostic Features of 51 Colorectal and 130 Appendiceal Cancer Patients with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy , 1995, Annals of surgery.

[29]  A. Kawabata,et al.  Clinical Availability of Tumour Biopsy Using Diagnostic Laparoscopy for Advanced Ovarian Cancer , 2021, In Vivo.

[30]  J. Escrig,et al.  Prognostic value of peritoneal cancer index in primary advanced ovarian cancer. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[31]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.